# Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences Canonical URL: https://biopharmsignal.com/news/EDIT/editas-medicine-announces-edit-401-oral-presentation-at-the-european-society-of--31fa9f7c Ticker: EDIT Company: Editas Medicine Source: Editas Medicine Published: 2025-10-06 13:00 EST ## Summary Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing... ## Article Body Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced an oral presentation at the upcoming European Society of Gene and Cell Therapy (ESGCT) Congress, to be held October 7-10, 2025, in Seville, Spain. European Society of Gene and Cell Therapy (ESGCT) Congress Title: A transformative LDL-cholesterol–lowering in vivo CRISPR gene editing medicine that functionally upregulates LDLR in mice and non-human primates Session Date and Time: Thursday, October 9, 5:00 p.m. CEST / 11:00 a.m. ET Session Title: 9A: Gene Editing II, Ex Vivo Applications Room: Parallel A Presenter: Linda Burkly, Ph.D, Executive Vice President and Chief Scientific Officer, Editas Medicine Final Abstract Number: OR069 Abstracts are available to registrants on the ESGCT website . The oral presentation will also be posted to the “ Posters & Presentations ” section of the Company’s website at the time of the presentation and will remain accessible following the event. In addition, management will participate in the following upcoming investor conferences in October: H.C. Wainwright Genetic Medicines Virtual Conference Format: Fireside Chat Date: Tuesday, October 14, 7:00 a.m. ET Location: Virtual Chardan 9 th Annual Genetic Medicines Conference Panel Discussion: Genome Editing: Next Wave Technologies Date: Tuesday, October 21, 8:45 a.m. ET Location: New York, NY To access a live webcast of the presentations, please visit the “Investors” section of the Company’s website at www.editasmedicine.com . An archived replay will be available for approximately 30 days following each event. About Editas Medicine As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com. ## Recent Company News - 2026-05-28 20:01 EST — [Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference](https://biopharmsignal.com/news/EDIT/editas-medicine-announces-updated-presentation-time-for-upcoming-investor-confer-ef3968d7) — Source: Editas Medicine - 2026-05-26 13:05 EST — [Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering](https://biopharmsignal.com/news/EDIT/editas-medicine-announces-pricing-of-up-to-319-4-million-public-offering-127eec22) — Source: Editas Medicine - 2026-05-26 10:15 EST — [Editas Medicine Announces Proposed Public Offering](https://biopharmsignal.com/news/EDIT/editas-medicine-announces-proposed-public-offering-1685aa73) — Source: Editas Medicine - 2026-05-26 10:01 EST — [Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress](https://biopharmsignal.com/news/EDIT/editas-medicine-presents-edit-401-preclinical-data-demonstrating-robust-reductio-8f1aef48) — Source: Editas Medicine - 2026-05-14 10:01 EST — [Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting](https://biopharmsignal.com/news/EDIT/editas-medicine-reports-new-preclinical-data-demonstrating-progress-of-edit-401--a6308965) — Source: Editas Medicine ## Related News - 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627) - 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922) - 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c) - 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec) - 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)